ARCHIVES

Drugs and Targets: FDA extends Lymphoseek label to include mapping in solid tumors

This article is from The Cancer Letter archive.

Vol. 40 No. 41 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable

January 31, 2003

In Brief: Last Two NCAB Choices Named; Hellman Heads ASCO, Sartorelli Named President Of AACR

May 16, 1986

Fredrickson, Upton Kill Plan To Convert FCRC To NIH Satellite, Will Continue L-B Contract

February 9, 1979

Thompson Tours Brown’s Brain Science Center.

March 16, 2001

DCE Makes Changes In Procedure For Occupational Studies

November 21, 1986

Cullen Credits Staff With Success Of STCP, Strong Prevention Program a NCI

May 19, 1989